EGFR and glioma: Further experiments revealed that TSPAN13 knockdown increased glioma cell sensitivity to carmustine, another alkylating agent, while showing no significant impact on sensitivity to the apoptosis inducer cisplatin or the EGFR inhibitor gefitinib.